Effect of aldosterone-producing adenoma on endothelial function and rho-associated kinase activity in patients with primary aldosteronism

Hypertension

Volumn 65, Issue 4, 2015, Pages 841-848

  Matsumoto, Takeshi ^a   Oki, Kenji ^a   Kajikawa, Masato ^a   Nakashima, Ayumu ^c   Maruhashi, Tatsuya ^a   Iwamoto, Yumiko ^a   Iwamoto, Akimichi ^a   Oda, Nozomu ^a   Hidaka, Takayuki ^a   Kihara, Yasuki ^a   Kohno, Nobuoki ^a   Chayama, Kazuaki ^b   Goto, Chikara ^d   Aibara, Yoshiki ^a   Noma, Kensuke ^a   Liao, James K ^e   Higashi, Yukihito ^a,c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^d HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

aldosterone; hyperaldosteronism; hypertension; Rho associated kinases

Indexed keywords

ALDOSTERONE; GLYCERYL TRINITRATE; POTASSIUM; RENIN; RHO KINASE;

ADRENALECTOMY; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL FUNCTION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ESSENTIAL HYPERTENSION; EVALUATION STUDY; FEMALE; FLOW MEDIATED VASODILATION; HUMAN; HYPERALDOSTERONISM; IDIOPATHIC DISEASE; IDIOPATHIC HYPERALDOSTERONISM; LAPAROSCOPIC SURGERY; LEUKOCYTE; MALE; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASODILATATION; ADENOMA; BLOOD; COMPLICATION; FOLLOW UP; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADENOMA; ADULT; ALDOSTERONE; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; RHO-ASSOCIATED KINASES; VASODILATION;

EID: 84929130184     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.05001     Document Type: Article

References (43)

1. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005; 45: 1243-1248. doi: 10.1016/j. jacc.2005.01.015
2. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled crosssectional study. Hypertension. 2013; 62: 331-336. doi: 10.1161/HYPERTENSIONAHA.113.01060
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340: 115-126. doi: 10.1056/NEJM199901143400207
4. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005; 111: 363-368. doi: 10.1161/01.CIR.0000153339.27064.14
5. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endotheliumdependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990; 323: 22-27. doi: 10.1056/NEJM199007053230105
6. Linder L, Kiowski W, Bühler FR, Lüscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation. 1990; 81: 1762-1767
7. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, Sudano I, Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation. 1995; 91: 1981-1987
8. Higashi Y, Sasaki S, Kurisu S, Yoshimizu A, Sasaki N, Matsuura H, Kajiyama G, Oshima T. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium-derived nitric oxide. Circulation. 1999; 100: 1194-1202
9. Furchgott RF. Role of endothelium in responses of vascular smooth muscle. Circ Res. 1983; 53: 557-573
10. Lüscher TF. Imbalance of endothelium-derived relaxing and contracting factors. A new concept in hypertension?. Am J Hypertens. 1990; 3: 317-330
11. Vanhoutte PM. Endothelium and control of vascular function. State of the Art lecture. Hypertension. 1989; 13(6 Pt 2): 658-667
12. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension. 2005; 46: 1227-1235. doi: 10.1161/01. HYP.0000193502.77417.17
13. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med. 2002; 346: 1954-1962. doi: 10.1056/NEJMoa013591
14. Higashi Y, Sasaki S, Nakagawa K, Kimura M, Sasaki S, Noma K, Matsuura H, Hara K, Goto C, Oshima T, Chayama K. Excess norepinephrine impairs both endothelium-dependent and -independent vasodilation in patients with pheochromocytoma. Hypertension. 2002; 39(2 Pt 2): 513-518
15. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004; 109: 2857-2861. doi: 10.1161/01.CIR.0000129307.26791.8E
16. Duffy SJ, Biegelsen ES, Eberhardt RT, Kahn DF, Kingwell BA, Vita JA. Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension. 2005; 46: 707-713. doi: 10.1161/01.HYP.0000184231.84465.62
17. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997; 389: 990-994. doi: 10.1038/40187
18. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science. 1997; 275: 1308-1311
19. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998; 279: 509-514
20. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension. 2001; 38: 1307-1310
21. Soga J, Noma K, Hata T, Hidaka T, Fujii Y, Idei N, Fujimura N, Mikami S, Maruhashi T, Kihara Y, Chayama K, Kato H, Liao JK, Higashi Y; ROCK Study Group. Rho-associated kinase activity, endothelial function, and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2011; 31: 2353-2359. doi: 10.1161/ATVBAHA.111.227892
22. Kajikawa M, Noma K, Maruhashi T, Mikami S, Iwamoto Y, Iwamoto A, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Nakashima A, Goto C, Liao JK, Higashi Y. Rho-associated kinase activity is a predictor of cardiovascular outcomes. Hypertension. 2014; 63: 856-864. doi: 10.1161/HYPERTENSIONAHA.113.02296
23. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, Dominiak P, Liao JK. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol. 2004; 24: 1842-1847. doi: 10.1161/01.ATV.0000142813.33538.82
24. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A; Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism-the Japan Endocrine Society 2009. Endocr J. 2011; 58: 711-721
25. Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Higashi Y. Nitroglycerine-induced vasodilation for assessment of vascular function: a comparison with flow-mediated vasodilation. Arterioscler Thromb Vasc Biol. 2013; 33: 1401-1408. doi: 10.1161/ATVBAHA.112.300934
26. Hashikabe Y, Suzuki K, Jojima T, Uchida K, Hattori Y. Aldosterone impairs vascular endothelial cell function. J Cardiovasc Pharmacol. 2006; 47: 609-613. doi: 10.1097/01.fjc.0000211738.63207.c3
27. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, Hirata Y, Naruse M. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension. 2006; 48: 165-171. doi: 10.1161/01.HYP.0000226054.53527.bb
28. Hao L, Kanno Y, Fukushima R, Watanabe Y, Ishida Y, Suzuki H. Effects of eplerenone on heart and kidney in two-kidney, one-clip rats. Am J Nephrol. 2004; 24: 54-60. doi: 10.1159/000075945
29. Kobayashi N, Hara K, Tojo A, Onozato ML, Honda T, Yoshida K, Mita S, Nakano S, Tsubokou Y, Matsuoka H. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension. 2005; 45: 538-544. doi: 10.1161/01.HYP.0000157408.43807.5a
30. Sanz-Rosa D, Oubiña MP, Cediel E, De las Heras N, Aragoncillo P, Balfagón G, Cachofeiro V, Lahera V. Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. Antioxid Redox Signal. 2005; 7: 1294-1301. doi: 10.1089/ars.2005.7.1294
31. Fujimura N, Noma K, Hata T, Soga J, Hidaka T, Idei N, Fujii Y, Mikami S, Maruhashi T, Iwamoto Y, Kihara Y, Chayama K, Kato H, Liao JK, Higashi Y; ROCK Study Group. Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. Clin Pharmacol Ther. 2012; 91: 289-297. doi: 10.1038/clpt.2011.227
32. Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart. 2004; 90: 765-770. doi: 10.1136/hrt.2003.017368
33. Dohi Y, Thiel MA, Bühler FR, Lüscher TF. Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. Hypertension. 1990; 16: 170-179
34. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993; 87: 1468-1474
35. Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension. 1994; 24: 499-505
36. Schiffrin EL, Deng LY. Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension. 1995; 25(4 Pt 2): 699-703
37. Iwatsubo H, Nagano M, Sakai T, Kumamoto K, Morita R, Higaki J, Ogihara T, Hata T. Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension. 1997; 29(1 Pt 2): 286-290
38. Higashi Y, Sasaki S, Nakagawa K, Ueda T, Yoshimizu A, Kurisu S, Matsuura H, Kajiyama G, Oshima T. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol. 2000; 35: 284-291
39. Miyata K, Hitomi H, Guo P, Zhang GX, Kimura S, Kiyomoto H, Hosomi N, Kagami S, Kohno M, Nishiyama A. Possible involvement of Rho-kinase in aldosterone-induced vascular smooth muscle cell remodeling. Hypertens Res. 2008; 31: 1407-1413. doi: 10.1291/hypres.31.1407
40. Doi T, Sakoda T, Akagami T, Naka T, Mori Y, Tsujino T, Masuyama T, Ohyanagi M. Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2008; 295: H1279-H1287. doi: 10.1152/ajpheart.00148.2008
41. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, Kimura S, Kiyomoto H, Ohmori K, Li DT, Abe Y, Nishiyama A. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol. 2006; 17: 2193-2201. doi: 10.1681/ASN.2005121375
42. Seasholtz TM, Zhang T, Morissette MR, Howes AL, Yang AH, Brown JH. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kip1) expression in the vasculature of hypertensive rats. Circ Res. 2001; 89: 488-495
43. Wehrwein EA, Northcott CA, Loberg RD, Watts SW. Rho/Rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension. J Pharmacol Exp Ther. 2004; 309: 1011-1019. doi: 10.1124/jpet.103.062265